trial · primary record
ianalumab
Primary Immune Thrombocytopenia (ITP)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 164 |
| Primary completion | 2030-08-31 |
| Primary endpoint | (Main cohort: Primary immune thrombocytopenia (ITP)): Percentages of participants who are tolerable to ianalumab (9 mg/kg) |
| Registry ID | NCT07421167 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:46.490Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07421167
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.